兆科眼科(06622.HK)獲Eyedetec Medical授予乾眼症醫療器械獨家分銷權
兆科眼科(06622.HK)公佈,與美國醫療器械公司Eyedetec Medical訂立獨家許可、供應及分銷協議,獲授予獨家權利,可於大中華地區(中國內地、香港、澳門 及臺灣)、南韓及東盟國家(汶萊、柬埔寨、印尼、老撾、馬來西亞、緬甸、菲律賓、新加坡、 泰國及越南),登記、進口、推廣、分銷、推銷及銷售用於就治療乾眼症的醫療器械Eye Lipid Mobilizer(ELM)。
Eyedetec Medical目前正爲ELM於美國食品藥物管理局上市前批準申請作準備,料獲批後將成爲第一個、也是唯一一個醫生處方、針對乾眼症根本原因進行治療的居家治療方案。
兆科眼科董事會主席、執行董事兼行政總裁李小羿表示,是次合作將擴大公司醫療器械組合,業務將覆蓋不同嚴重程度的乾眼症患者羣體。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.